玻璃体内甲氨蝶呤联合免疫化疗后减量全脑放疗治疗新诊断B细胞原发性眼内淋巴瘤
本研究对17例新诊断B细胞原发性眼内淋巴瘤(伴或不伴中枢神经系统受累)采用玻璃体内甲氨蝶呤注射、甲氨蝶呤为基础的全身诱导化疗及大剂量阿糖胞苷巩固后减量全脑放疗(23.4 Gy)的联合方案,16例完成治疗。中位随访48.9个月,4年无进展生存率为74.9%,4年总生存率为86.3%,2例出现中枢神经系统复发,3例眼内复发;MRI白质异常在放疗后4年显著增加,但仅1例出现轻度认知功能障碍。
要点
- 联合方案治疗B细胞原发性眼内淋巴瘤,4年PFS为74.9%,4年OS为86.3%。
- 17例中2例中枢神经系统复发、3例眼内复发,16例完成方案。
- 减量全脑放疗23.4 Gy后4年MRI白质异常显著增加,仅1例轻度认知障碍。
核心结论
- 玻璃体内化疗、预防性全身化疗和减量全脑放疗联合方案对原发性眼内淋巴瘤显示出降低中枢神经系统复发率、改善4年PFS和OS的潜力,且未增加认知功能障碍。
研究设计与样本
- 研究纳入新诊断B细胞原发性眼内淋巴瘤伴或不伴中枢神经系统受累患者,采用玻璃体内甲氨蝶呤注射、甲氨蝶呤为基础的全身诱导化疗及大剂量阿糖胞苷巩固后减量全脑放疗(23.4 Gy)的联合治疗方案。
- 17例患者开始方案治疗,16例完成方案治疗。
主要发现
- 全组17例中,中枢神经系统复发2例,眼内复发3例;4年无进展生存率为74.9%,4年总生存率为86.3%,中位随访48.9个月。
- 无中枢神经系统受累的11例患者中,中枢神经系统复发1例,眼内复发3例;4年无进展生存率为72.7%,4年总生存率为88.9%。
- 减量全脑放疗后4年,MRI显示的白质异常显著增加,但仅1例患者出现轻度认知功能障碍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary intraocular lymphoma (IOL) has a propensity for central nervous system (CNS) relapse within 2 years of initial diagnosis, affecting clinical outcome. To reduce CNS relapse, we performed the combination treatment protocols of intravitreal methotrexate injections, methotrexate-based systemic induction chemotherapy and consolidation high-dose cytarabine and reduced-dose whole brain radiation therapy (rdWBRT, 23·4 Gy) for B-cell primary IOL with or without newly diagnosed CNS involvement. All patients underwent longitudinal brain magnetic resonance imaging (MRI) and cognitive assessment for evaluation of treatment-induced leucoencephalopathy. Seventeen patients initiated and 16 completed the protocol treatment. CNS relapse occurred in 2 patients and intraocular relapse in 3. Four-year progression-free survival (PFS) was 74·9% and 4-year overall survival (OS) was 86·3%, with a median follow-up period of 48·9 months. Of 11 patients without CNS involvement, 1 had CNS relapse and 3 intraocular relapse, and 4-year PFS and OS was 72·7% and 88·9%, respectively. Although white matter abnormalities shown by MRI were significantly increased at 4 years after rdWBRT, only one patient developed mild cognitive impairment. The combination of intravitreal chemotherapy, prophylactic systemic chemotherapy and rdWBRT for primary IOL showed a potential to reduce CNS relapse rate and improved 4-year PFS and OS without increase of cognitive dysfunction.
引用
- Kaburaki T, Taoka K, Matsuda J, et al. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br J Haematol. 2017. PMID: 28699673. doi:10.1111/bjh.14848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。